Cordis puts the nitric oxide (NO) in restenosis:
This article was originally published in Clinica
Cordis and NitroMed are collaborating to develop a stent that gives off nitric oxide in an attempt to prevent restenosis. Restenosis, the re-narrowing of arteries after angioplasty, is caused by a combination of elastic recoil and uncontrolled division of cells in response to wounding. Nitric oxide can suppress the cell proliferation. Cordis and NitroMed will develop a stent coated with a nitric oxide donor for use in a variety of cardiovascular applications.
You may also be interested in...
Azar says ACIP’s prioritization recommendations should carry weight, but states will be final arbiter of who is vaccinated.
Sanofi R&D head John Reed says the company has kept 95% of patients on its nearly 400 clinical trials, started 59 studies, and benefited from its in-house drug supply management.
The funding will be used to support clinical and preclinical development at its portfolio companies, with 8-10 programs in the clinic in 2021.